Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Drug Therapy"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 283286
Tytuł:
Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma.
Autorzy:
Zhu M; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Jin M; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.; Department of Radiation Therapy, The First Hospital of Jilin University, Changchun, 130021, China.
Zhao X; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
Shen S; Department of Liver Surgery, Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Chen Y; Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen University, Guangzhou, 510080, China.; Department of Histology and Embryology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Xiao H; Division of Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Wei G; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China.
He Q; Department of Liver Surgery, Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Li B; Clinical Trials Unit, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China.
Peng Z; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510080, China. .; Clinical Trials Unit, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. .; Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. .; Cancer Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, China. .; Department of Radiation Oncology, Clinical Trials Unit, Institute of Precision Medicine, Cancer Center, The First Affiliated Hospital of Sun Yat-sen University, No.58 Zhongshan Road 2, Yuexiu District, Guangzhou, 510080, Guangdong, China. .
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2024 Apr 19; Vol. 22 (1), pp. 165. Date of Electronic Publication: 2024 Apr 19.
Typ publikacji:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Cholangiocarcinoma*/drug therapy
Cholangiocarcinoma*/radiotherapy
Drug-Related Side Effects and Adverse Reactions*
Bile Duct Neoplasms*/drug therapy
Bile Duct Neoplasms*/radiotherapy
Humans ; Immunotherapy/adverse effects ; Drug Therapy, Combination ; Bile Ducts, Intrahepatic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Variables associated with antibiotic treatment tolerance in patients with Mycobacterium avium complex pulmonary disease.
Autorzy:
Marmor M; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America. .
Sharifi H; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.
Jacobs S; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.
Fazeli K; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.
Ruoss S; Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, United States of America.
Pokaż więcej
Źródło:
Respiratory research [Respir Res] 2024 Mar 11; Vol. 25 (1), pp. 123. Date of Electronic Publication: 2024 Mar 11.
Typ publikacji:
Review; Journal Article
MeSH Terms:
Mycobacterium avium-intracellulare Infection*/diagnosis
Mycobacterium avium-intracellulare Infection*/drug therapy
Mycobacterium avium-intracellulare Infection*/microbiology
Lung Diseases*/diagnosis
Lung Diseases*/drug therapy
Lung Diseases*/epidemiology
Liver Diseases*
Humans ; Mycobacterium avium Complex ; Retrospective Studies ; Drug Therapy, Combination ; Anti-Bacterial Agents/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The prevalence, clinical reasoning and impact of non-standard anti-tuberculosis regimens at the initial prescription.
Autorzy:
Chen RT; Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan.
Liu CY; Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan.
Lin SY; College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University Hospital, No 7, Chung Shan South Road, Taipei, Taiwan.
Shu CC; College of Medicine, National Taiwan University, Taipei, Taiwan. .; Department of Internal Medicine, National Taiwan University Hospital, No 7, Chung Shan South Road, Taipei, Taiwan. .
Sheng WH; College of Medicine, National Taiwan University, Taipei, Taiwan.; Department of Internal Medicine, National Taiwan University Hospital, No 7, Chung Shan South Road, Taipei, Taiwan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 07; Vol. 14 (1), pp. 5631. Date of Electronic Publication: 2024 Mar 07.
Typ publikacji:
Journal Article
MeSH Terms:
Tuberculosis*/drug therapy
Tuberculosis*/epidemiology
Tuberculosis, Multidrug-Resistant*/drug therapy
Gout*/drug therapy
Humans ; Antitubercular Agents/therapeutic use ; Prevalence ; Drug Therapy, Combination ; Clinical Reasoning
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clopidogrel with indobufen or aspirin in minor ischemic stroke or high-risk transient ischemic attack: a randomized controlled clinical study.
Autorzy:
Liu X; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Lv X; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Peng Y; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Wang J; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Lei J; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Tang C; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Luo S; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Mai W; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Cai Y; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Fan Q; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Liu C; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China.
Zhang L; The Fifth Affiliated Hospital of Sun Yat-sen University, No. 52 Meihua East Road, Zhuhai City, Guangdong Province, China. .
Pokaż więcej
Źródło:
BMC neurology [BMC Neurol] 2024 Mar 01; Vol. 24 (1), pp. 81. Date of Electronic Publication: 2024 Mar 01.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Ischemic Attack, Transient*/drug therapy
Ischemic Attack, Transient*/epidemiology
Ischemic Stroke*/drug therapy
Stroke*/drug therapy
Phenylbutyrates*
Isoindoles*
Humans ; Aspirin ; Clopidogrel/therapeutic use ; Platelet Aggregation Inhibitors/adverse effects ; Prospective Studies ; Hemorrhage/chemically induced ; Drug Therapy, Combination ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and tolerability of adjunctive lacosamide in patients aged <4 years with focal seizures.
Autorzy:
Makedonska I; Municipal Non-profit Enterprise City Children's Clinical Hospital #6 of Dnipro City Council, Dnipro, Ukraine.
Ng YT; Baylor College of Medicine/The Children's Hospital of San Antonio, San Antonio, Texas, USA.
Beller C; UCB Pharma, Morrisville, North Carolina, USA.
Bozorg A; UCB Pharma, Morrisville, North Carolina, USA.
Csikós J; UCB Pharma, Monheim am Rhein, Germany.
McClung C; UCB Pharma, Morrisville, North Carolina, USA.
Moeltgen H; UCB Pharma, Monheim am Rhein, Germany.
Farkas MK; Pediatric Center, MTA Center of Excellence, Semmelweis University, Budapest, Hungary.
Pokaż więcej
Corporate Authors:
SP0967 Study Group
Źródło:
Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2024 Mar; Vol. 11 (3), pp. 768-779. Date of Electronic Publication: 2024 Feb 20.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Anticonvulsants*/adverse effects
Epilepsies, Partial*/drug therapy
Adult ; Child ; Humans ; Child, Preschool ; Lacosamide/adverse effects ; Reproducibility of Results ; Acetamides/adverse effects ; Drug Therapy, Combination ; Dose-Response Relationship, Drug ; Treatment Outcome ; Seizures/drug therapy ; Seizures/chemically induced
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
Autorzy:
Semitala FC; Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda.; Infectious Diseases Research Collaboration, Kampala, Uganda.; Makerere University Joint AIDS Program, Kampala Uganda.
Kadota JL; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Musinguzi A; Infectious Diseases Research Collaboration, Kampala, Uganda.
Welishe F; Infectious Diseases Research Collaboration, Kampala, Uganda.
Nakitende A; Infectious Diseases Research Collaboration, Kampala, Uganda.
Akello L; Infectious Diseases Research Collaboration, Kampala, Uganda.
Kunihira Tinka L; Infectious Diseases Research Collaboration, Kampala, Uganda.
Nakimuli J; Infectious Diseases Research Collaboration, Kampala, Uganda.
Ritar Kasidi J; Infectious Diseases Research Collaboration, Kampala, Uganda.
Bishop O; Infectious Diseases Research Collaboration, Kampala, Uganda.
Nakasendwa S; Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.
Baik Y; Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Patel D; The Better Lab and Department of Surgery, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Sammann A; The Better Lab and Department of Surgery, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Nahid P; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Belknap R; Denver Health and Hospital Authority and Division of Infectious Diseases, Department of Medicine, University of Colorado, Denver, Colorado, United States of America.
Kamya MR; Makerere University, Department of Medicine, College of Health Sciences, Kampala, Uganda.; Infectious Diseases Research Collaboration, Kampala, Uganda.
Handley MA; Center for Vulnerable Populations, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.
Phillips PP; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Katahoire A; Child Health and Development Center, School of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Berger CA; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California San Francisco, San Francisco, California, United States of America.
Kiwanuka N; Department of Epidemiology and Biostatistics, School of Public Health, Makerere University College of Health Sciences, Kampala, Uganda.
Katamba A; Clinical Epidemiology & Biostatistics Unit, Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.; Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.
Dowdy DW; Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Cattamanchi A; Center for Tuberculosis, University of California San Francisco, San Francisco, California, United States of America.; Uganda Tuberculosis Implementation Research Consortium, Walimu, Kampala, Uganda.; Division of Pulmonary Diseases and Critical Care Medicine, University of California Irvine, Irvine, California, United States of America.
Pokaż więcej
Źródło:
PLoS medicine [PLoS Med] 2024 Feb 20; Vol. 21 (2), pp. e1004356. Date of Electronic Publication: 2024 Feb 20 (Print Publication: 2024).
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Tuberculosis*/drug therapy
Tuberculosis*/prevention & control
Latent Tuberculosis*/drug therapy
HIV Infections*/complications
HIV Infections*/drug therapy
Rifampin/*analogs & derivatives
Humans ; Isoniazid/adverse effects ; Antitubercular Agents/adverse effects ; Uganda ; Drug Therapy, Combination
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Several first-line anti-hypertensives act on fibrosarcoma progression and PD1ab blockade therapy.
Autorzy:
Sun J; Department of Orthopaedics, The First Affiliated Hospital of Jishou University, The People's Hospital of Xiangxi Autonomous Prefecture, Jishou, China.
Zhang C; Department of Jishou University, Jishou, China.
Su X; Department of Jishou University, Jishou, China.
Zhou H; Department of Medicine, Taizhou University, Zhejiang, China.
Zhou S; Department of Medicine, Taizhou University, Zhejiang, China.
Jiang M; Department of Medicine, Taizhou University, Zhejiang, China.
Fang B; Department of Medicine, Taizhou University, Zhejiang, China. .
Pokaż więcej
Źródło:
Journal of orthopaedic surgery and research [J Orthop Surg Res] 2024 Feb 19; Vol. 19 (1), pp. 147. Date of Electronic Publication: 2024 Feb 19.
Typ publikacji:
Journal Article
MeSH Terms:
Hypertension*/drug therapy
Fibrosarcoma*/drug therapy
Humans ; Antihypertensive Agents/therapeutic use ; Losartan/pharmacology ; Losartan/therapeutic use ; Captopril/pharmacology ; Captopril/therapeutic use ; Spironolactone/therapeutic use ; Furosemide/therapeutic use ; CD8-Positive T-Lymphocytes ; Hydrochlorothiazide/therapeutic use ; Drug Therapy, Combination ; Verapamil/pharmacology ; Verapamil/therapeutic use ; Solute Carrier Family 12, Member 3
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Association between failed eradication of 7-day triple therapy for Helicobacter pylori and untreated dental caries in Japanese adults.
Autorzy:
Iwai K; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan.
Azuma T; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan.
Yonenaga T; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan.
Sasai Y; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan.
Watanabe K; Asahi University Hospital, 3-23 Hashimoto-Cho, Gifu, Gifu, 500-8523, Japan.
Obora A; Asahi University Hospital, 3-23 Hashimoto-Cho, Gifu, Gifu, 500-8523, Japan.
Deguchi F; Asahi University Hospital, 3-23 Hashimoto-Cho, Gifu, Gifu, 500-8523, Japan.
Kojima T; Asahi University Hospital, 3-23 Hashimoto-Cho, Gifu, Gifu, 500-8523, Japan.
Tomofuji T; Department of Community Oral Health, School of Dentistry, Asahi University, 1851-1 Hozumi, Mizuho, Gifu, 501-0296, Japan. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 19; Vol. 14 (1), pp. 4043. Date of Electronic Publication: 2024 Feb 19.
Typ publikacji:
Journal Article
MeSH Terms:
Helicobacter pylori*
Dental Caries*/drug therapy
Helicobacter Infections*/complications
Helicobacter Infections*/drug therapy
Anti-Infective Agents*/therapeutic use
Adult ; Humans ; Anti-Bacterial Agents/therapeutic use ; Cross-Sectional Studies ; Japan/epidemiology ; Drug Therapy, Combination ; Treatment Outcome ; Clarithromycin/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Exploring the Roles of Vitamins C and D and Etifoxine in Combination with Citalopram in Depression/Anxiety Model: A Focus on ICAM-1, SIRT1 and Nitric Oxide.
Autorzy:
Gammoh O; Department of Clinical Pharmacy and Pharmacy, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.
Ibrahim A; Faculty of Sciences, Yarmouk University, Irbid 21163, Jordan.
Yehya A; Department of Clinical Pharmacy and Pharmacy, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.
Alqudah A; Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmaceutical Sciences, The Hashemite University, Zarqa 13133, Jordan.
Qnais E; Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa 13133, Jordan.
Altaber S; Department of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa 13133, Jordan.
Alrob OA; Department of Clinical Pharmacy and Pharmacy, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.
Aljabali AAA; Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid 21163, Jordan.
Tambuwala MM; Lincoln Medical School, Brayford Pool Campus, University of Lincoln, Lincoln LN6 7TS, UK.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 06; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 06.
Typ publikacji:
Journal Article
MeSH Terms:
Anxiety*/drug therapy
Citalopram*/pharmacology
Citalopram*/therapeutic use
Depression*/drug therapy
Nitric Oxide*
Oxazines*/pharmacology
Oxazines*/therapeutic use
Animals ; Mice ; Antidepressive Agents/pharmacology ; Antidepressive Agents/therapeutic use ; Ascorbic Acid/pharmacology ; Ascorbic Acid/therapeutic use ; Intercellular Adhesion Molecule-1 ; Sirtuin 1 ; Vitamin D/pharmacology ; Vitamin D/therapeutic use ; Vitamins ; Drug Therapy, Combination
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the ASPIRATION registry.
Autorzy:
Dai C; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Liu M; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Yang Z; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Li Y; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Zhou Y; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Lu D; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Xia Y; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Chen A; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Li C; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Lu H; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Dai Y; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Ma J; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China.; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China.
Chen Z; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China. .; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .
Qian J; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China. .; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .
Ge J; Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai, 200032, China. .; National Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .; Shanghai Clinical Research Center for Interventional Medicine, 180 Fenglin Road, Shanghai, 200032, China. .
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2024 Apr 02; Vol. 22 (1), pp. 148. Date of Electronic Publication: 2024 Apr 02.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
Acute Coronary Syndrome*/drug therapy
Acute Coronary Syndrome*/surgery
Isoindoles*
Percutaneous Coronary Intervention*/adverse effects
Percutaneous Coronary Intervention*/methods
Phenylbutyrates*
Humans ; Aspirin/adverse effects ; Drug Therapy, Combination ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Platelet Aggregation Inhibitors/adverse effects ; Registries ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques.
Autorzy:
Lim SY; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Lee J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Osuna CE; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Vikhe P; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Schalk DR; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Chen E; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Fray E; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Kumar M; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Schultz-Darken N; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Rakasz E; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Capuano S; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Ladd RA; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Gil HM; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Evans DT; Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
Jeng EK; Altor Biosciences, Miramar, FL 33027, USA.
Seaman M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Martin M; Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Van Dorp C; Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
Perelson AS; Los Alamos National Laboratory, Los Alamos, NM 87545, USA.; Santa Fe Institute, Santa Fe, NM 87501, USA.
Wong HC; Altor Biosciences, Miramar, FL 33027, USA.
Siliciano JD; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Siliciano R; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.; Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Safrit JT; ImmunityBio, Culver City, CA 90232, USA.
Nixon DF; Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
Soon-Shiong P; ImmunityBio, Culver City, CA 90232, USA.
Nussenzweig M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.; Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.
Whitney JB; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.; Department of Biology, Boston College, Chestnut Hill, MA 02467, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2024 Mar 08; Vol. 383 (6687), pp. 1104-1111. Date of Electronic Publication: 2024 Feb 29.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-Retroviral Agents*/therapeutic use
Anti-Retroviral Agents*/pharmacology
Simian Acquired Immunodeficiency Syndrome*/drug therapy
Simian Acquired Immunodeficiency Syndrome*/therapy
Simian Immunodeficiency Virus*
Recombinant Fusion Proteins*/administration & dosage
Recombinant Fusion Proteins*/pharmacology
Animals ; Humans ; Broadly Neutralizing Antibodies/administration & dosage ; CD8-Positive T-Lymphocytes/virology ; Immunotherapy ; Macaca mulatta ; Viral Load ; Remission Induction ; Drug Therapy, Combination
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes.
Autorzy:
Ali RA; Zoology Department, Faculty of Science, South Valley University, Qena, Egypt.
Awadalla EA; Zoology Department, Faculty of Science, Aswan University, Aswan, Egypt.
Amin YA; Department of Theriogenology, Faculty of Veterinary Medicine, Aswan University, Aswan, Egypt. .
Fouad SS; Qena University Hospital, South Valley University, Qena, Egypt.
Ahmed MAB; Department of Anatomy, Faculty of Medicine, South Valley University, Qena, Egypt.
Hassan MH; Department of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena, Egypt.
Abdel-Kahaar E; Department of Medical Pharmacology, Faculty of Medicine, South Valley University, Qena, Egypt.; Institute of Clinical Pharmacology, Medical Faculty Mannheim, Ruprecht-Karls-University, Heidelberg, Germany.
Abdel-Aziz RH; Department of Medical Physiology, Faculty of Medicine, South Valley University, Qena, Egypt.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Mar 07; Vol. 14 (1), pp. 5682. Date of Electronic Publication: 2024 Mar 07.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis C, Chronic*/drug therapy
Pancreatitis*/chemically induced
Humans ; Adult ; Child ; Male ; Animals ; Rats ; Antiviral Agents/adverse effects ; Sofosbuvir/adverse effects ; Ribavirin/therapeutic use ; Hepacivirus/genetics ; Acute Disease ; Treatment Outcome ; Drug Therapy, Combination ; Semen ; Sperm Motility ; Liver Cirrhosis/complications ; Lipase/genetics ; Genotype
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies.
Autorzy:
Underwood M; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Urbaityte R; GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Wang R; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Horton J; Parexel, 2520 Meridian Parkway, Durham, NC 27713, USA.
Oyee J; GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Wynne B; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Fox D; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Jones B; ViiV Healthcare, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Man C; ViiV Healthcare, 406 Blackwell Street, Suite 300, Durham, NC 27701, USA.
Sievers J; ViiV Healthcare, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK.
Pokaż więcej
Źródło:
Viruses [Viruses] 2024 Mar 06; Vol. 16 (3). Date of Electronic Publication: 2024 Mar 06.
Typ publikacji:
Journal Article
MeSH Terms:
HIV Infections*/drug therapy
Anti-HIV Agents*/therapeutic use
HIV-1*
HIV Seropositivity*
Oxazines*
Piperazines*
Pyridones*
Adult ; Humans ; Lamivudine/therapeutic use ; Emtricitabine/therapeutic use ; Tenofovir/therapeutic use ; Drug Therapy, Combination ; Heterocyclic Compounds, 3-Ring/therapeutic use ; Viral Load ; Virus Replication
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical outcomes and risk factors for immune recovery and all-cause mortality in Latin Americans living with HIV with virological success: a retrospective cohort study.
Autorzy:
Castillo-Rozas G; Laboratory of Molecular and Cellular Virology, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile, Santiago, Chile.; HIV/AIDS Workgroup, Faculty of Medicine, University of Chile, Santiago, Chile.
Tu S; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Luz PM; Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil.
Mejia F; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú.
Sierra-Madero J; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México.
Rouzier V; Groupe Haitien d'Etudes du Sarcome de Kaposi et des Infections Opportunistes, Port-au-Prince, Haiti.
Shepherd BE; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Cortes CP; HIV/AIDS Workgroup, Faculty of Medicine, University of Chile, Santiago, Chile.; Department of Internal Medicine, Faculty of Medicine, University of Chile, Santiago, Chile.; Hospital Clínico San Borja Arriarán & Fundación Arriarán, Santiago, Chile.; Millenium Institute on Immunology and Immunotherapy, Santiago, Chile.
Pokaż więcej
Źródło:
Journal of the International AIDS Society [J Int AIDS Soc] 2024 Mar; Vol. 27 (3), pp. e26214.
Typ publikacji:
Journal Article
MeSH Terms:
HIV Infections*
Acquired Immunodeficiency Syndrome*/drug therapy
Anti-HIV Agents*/therapeutic use
Humans ; Male ; Retrospective Studies ; Risk Factors ; Drug Therapy, Combination ; CD4 Lymphocyte Count ; Viral Load ; Antiretroviral Therapy, Highly Active
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.
Autorzy:
Kishi T; Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Sakuma K; Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Hatano M; Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Matsuda Y; Department of Psychiatry, Jikei University School of Medicine, Minato, Tokyo, Japan.
Esumi S; Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Hyogo, Japan.
Miyake N; Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Miura I; Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
Hori H; Department of Psychiatry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
Kato M; Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.
Iwata N; Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Pokaż więcej
Źródło:
Neuropsychopharmacology reports [Neuropsychopharmacol Rep] 2024 Mar; Vol. 44 (1), pp. 216-220. Date of Electronic Publication: 2023 Aug 30.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Depressive Disorder, Major*/drug therapy
Adult ; Humans ; Japan ; Antidepressive Agents/therapeutic use ; Drug Therapy, Combination ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial.
Autorzy:
Zandifar A; Social Determinants of Health Research Center, Alborz University of Medical Sciences, Karaj, Iran.; Department of Psychiatry, Imam Hossein Hospital, Alborz University of Medical Sciences, Karaj, Alborz, Iran.
Panahi M; Faculty of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
Badrfam R; Department of Psychiatry, Imam Hossein Hospital, Alborz University of Medical Sciences, Karaj, Alborz, Iran. .
Qorbani M; Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.; Chronic Diseases Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło:
BMC psychiatry [BMC Psychiatry] 2024 Feb 26; Vol. 24 (1), pp. 163. Date of Electronic Publication: 2024 Feb 26.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Benzhydryl Compounds*
Citalopram*/therapeutic use
Depressive Disorder, Major*/drug therapy
Glucosides*
Humans ; Antidepressive Agents/therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Treatment Outcome ; Adolescent ; Young Adult ; Adult ; Middle Aged
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
COVID vaccine-induced lupus nephritis: Case report and review of the literature.
Autorzy:
Salas A; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Fatola A; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Krimins R; Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kamel IR; Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Geetha D; Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Fine D; Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Monroy-Trujillo M; Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Rosenberg A; Division of Kidney-Urologic Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Arend L; Division of Kidney-Urologic Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Timlin H; Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA.
Pokaż więcej
Źródło:
Lupus [Lupus] 2024 Feb; Vol. 33 (2), pp. 176-182. Date of Electronic Publication: 2024 Jan 02.
Typ publikacji:
Review; Case Reports; Journal Article
MeSH Terms:
Lupus Nephritis*/drug therapy
COVID-19*
Lupus Erythematosus, Systemic*/chemically induced
Vaccines*
Humans ; Female ; Immunosuppressive Agents/therapeutic use ; COVID-19 Vaccines ; Drug Therapy, Combination ; Mycophenolic Acid/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2018.
Autorzy:
Ngasala B; Department of Parasitology, Muhimbili University of Health and Allied Sciences, P.O. Box 65011, Dar es Salaam, Tanzania. .
Chiduo MG; Tanga Research Centre, National Institute for Medical Research, P.O Box 5004, Tanga, Tanzania.
Bushukatale S; Department of Parasitology, Muhimbili University of Health and Allied Sciences, P.O. Box 65011, Dar es Salaam, Tanzania.
Mmbando BP; Tanga Research Centre, National Institute for Medical Research, P.O Box 5004, Tanga, Tanzania.
Makene T; Department of Parasitology, Muhimbili University of Health and Allied Sciences, P.O. Box 65011, Dar es Salaam, Tanzania.
Kamugisha E; Catholic University of Health and Allied Sciences/Bugando Medical Centre, P. O Box 1464, Mwanza, Tanzania.
Ahmed M; Catholic University of Health and Allied Sciences/Bugando Medical Centre, P. O Box 1464, Mwanza, Tanzania.
Mandara CI; Tanga Research Centre, National Institute for Medical Research, P.O Box 5004, Tanga, Tanzania.; National Institute for Medical Research, Headquarters, P.O. Box 9653, Dar-es-Salaam, Tanzania.
Francis F; Tanga Research Centre, National Institute for Medical Research, P.O Box 5004, Tanga, Tanzania.
Mahende MK; Ifakara Health Institute Dar es Salaam Office, P. O. Box 78373, Dar es Salaam, Tanzania.
Kavishe RA; Kilimanjaro Christian Medical Centre, P.O. Box 3010, Moshi, Tanzania.
Muro F; Kilimanjaro Christian Medical Centre, P.O. Box 3010, Moshi, Tanzania.
Ishengoma DS; National Institute for Medical Research, Headquarters, P.O. Box 9653, Dar-es-Salaam, Tanzania.
Mandike R; National Malaria Control Programme (NMCP), P.O. Box 743, Dodoma, Tanzania.
Molteni F; National Malaria Control Programme (NMCP), P.O. Box 743, Dodoma, Tanzania.
Chacky F; National Malaria Control Programme (NMCP), P.O. Box 743, Dodoma, Tanzania.
Kitojo C; U.S. President's Malaria Initiative, U.S. Agency for International Development, Dar es Salaam, Tanzania.
Greer G; U.S. President's Malaria Initiative, U.S. Agency for International Development, Dar es Salaam, Tanzania.
Bishanga D; Department of Community Health, Muhimbili University of Health and Allied Sciences, P.O. Box 65011, Dar es Salaam, Tanzania.
Chadewa J; Jhpiego, Boresha Afya, P.O. Box 9170, Dar es Salaam, Tanzania.
Njau R; World Health Organization Country Office, P.O Box 9292, Dar es Salaam, Tanzania.
Warsame M; Gothenburg University, Gothenburg, Sweden.
Kabula B; RTI International, Dar es Salaam, Tanzania.
Nyinondi SS; RTI International, Dar es Salaam, Tanzania.
Reaves E; U.S. President's Malaria Initiative, U.S. Centers for Disease Control and Prevention, Dar es Salaam, Tanzania.
Mohamed A; National Malaria Control Programme (NMCP), P.O. Box 743, Dodoma, Tanzania.
Pokaż więcej
Źródło:
Malaria journal [Malar J] 2024 Apr 06; Vol. 23 (1), pp. 95. Date of Electronic Publication: 2024 Apr 06.
Typ publikacji:
Journal Article
MeSH Terms:
Antimalarials*/adverse effects
Artemisinins*/adverse effects
Malaria, Falciparum*/drug therapy
Malaria, Falciparum*/prevention & control
Malaria*/drug therapy
Child ; Humans ; Artemether, Lumefantrine Drug Combination/adverse effects ; Tanzania ; Reinfection/chemically induced ; Reinfection/drug therapy ; Artemether/therapeutic use ; Amodiaquine/therapeutic use ; Fever/drug therapy ; Drug Combinations ; Ethanolamines/adverse effects ; Plasmodium falciparum
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Post-treatment with maropitant reduces oxidative stress, endoplasmic reticulum stress and neuroinflammation on peripheral nerve injury in rats.
Autorzy:
Niella RV; Department of Agricultural and Environmental Sciences, State University of Santa Cruz, Ilhéus, Brazil.
Corrêa JMX; Department of Agricultural and Environmental Sciences, State University of Santa Cruz, Ilhéus, Brazil.
Dos Santos JFR; Department of Agricultural and Environmental Sciences, State University of Santa Cruz, Ilhéus, Brazil.
Lima LF; Department of Agricultural and Environmental Sciences, State University of Santa Cruz, Ilhéus, Brazil.
Marques CSDC; Department of Agricultural and Environmental Sciences, State University of Santa Cruz, Ilhéus, Brazil.
Santos LC; Department of Biological Sciences, State University of Santa Cruz, Ilhéus, Brazil.
Santana LR; Department of Agricultural and Environmental Sciences, State University of Santa Cruz, Ilhéus, Brazil.
Silva ÁJC; Department of Agricultural and Environmental Sciences, State University of Santa Cruz, Ilhéus, Brazil.
Farias KS; Department of Biological Sciences, State University of Santa Cruz, Ilhéus, Brazil.
Pirovani CP; Department of Biological Sciences, State University of Santa Cruz, Ilhéus, Brazil.
Silva JF; Department of Biological Sciences, State University of Santa Cruz, Ilhéus, Brazil.
de Lavor MSL; Department of Agricultural and Environmental Sciences, State University of Santa Cruz, Ilhéus, Brazil.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Mar 20; Vol. 19 (3), pp. e0287390. Date of Electronic Publication: 2024 Mar 20 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Peripheral Nerve Injuries*/drug therapy
Neuralgia*/drug therapy
Neuralgia*/metabolism
Quinuclidines*
Rats ; Male ; Animals ; Antioxidants/metabolism ; Rats, Wistar ; Neuroinflammatory Diseases ; Tumor Necrosis Factor-alpha/metabolism ; Interleukin-10/metabolism ; NF-E2-Related Factor 2/metabolism ; Prospective Studies ; Oxidative Stress ; Hyperalgesia/drug therapy ; Endoplasmic Reticulum Stress ; Superoxide Dismutase/metabolism ; Hypoxia/drug therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Connexin43, A Promising Target to Reduce Cardiac Arrhythmia Burden in Pulmonary Arterial Hypertension.
Autorzy:
Sykora M; Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 84104 Bratislava, Slovakia.
Szeiffova Bacova B; Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 84104 Bratislava, Slovakia.
Andelova K; Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 84104 Bratislava, Slovakia.
Egan Benova T; Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 84104 Bratislava, Slovakia.
Martiskova A; Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 84104 Bratislava, Slovakia.
Kurahara LH; Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University, Takamatsu 761-0793, Japan.
Hirano K; Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University, Takamatsu 761-0793, Japan.
Tribulova N; Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, 84104 Bratislava, Slovakia.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Mar 14; Vol. 25 (6). Date of Electronic Publication: 2024 Mar 14.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Pulmonary Arterial Hypertension*/drug therapy
Hypertension*/drug therapy
Heart Failure*/drug therapy
Humans ; Connexin 43/metabolism ; Arrhythmias, Cardiac/drug therapy ; Arrhythmias, Cardiac/etiology ; Anti-Arrhythmia Agents/pharmacology ; Anti-Arrhythmia Agents/therapeutic use ; Cardiac Conduction System Disease ; Familial Primary Pulmonary Hypertension/complications ; Inflammation/drug therapy
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 283286

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies